trending Market Intelligence /marketintelligence/en/news-insights/trending/BtcZibOhgaQAefxKTe0qvA2 content esgSubNav
In This List

Moody's: Pfizer's sale of consumer healthcare business is positive for liquidity

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Moody's: Pfizer's sale of consumer healthcare business is positive for liquidity

Moody's said a sale by Pfizer Inc. of its consumer healthcare business would have a positive impact on the company's liquidity.

The rating agency believes that Pfizer will have flexibility in deciding how to redeploy the proceeds from the asset sale, which would outweigh the modest loss of earnings and product diversification from the business.

Moody's said the sale of the business does not have any impact on Pfizer's ratings and outlook.